Pathological activation of MR leads to an increased risk for cardiovascular (CV) events [7, 8] and MR blockade using the marketed MR antagonists (MRA) spironolactone and eplerenone has proven to be an effective therapy for treatment of heart failure and hypertension [9–11]. The gene discussed is NR3C2; the disease is heart failure.